756 related articles for article (PubMed ID: 28780364)
1. The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study.
Bagel J; Duffin KC; Moore A; Ferris LK; Siu K; Steadman J; Kianifard F; Nyirady J; Lebwohl M
J Am Acad Dermatol; 2017 Oct; 77(4):667-674. PubMed ID: 28780364
[TBL] [Abstract][Full Text] [Related]
2. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study.
Blauvelt A; Reich K; Tsai TF; Tyring S; Vanaclocha F; Kingo K; Ziv M; Pinter A; Vender R; Hugot S; You R; Milutinovic M; Thaçi D
J Am Acad Dermatol; 2017 Jan; 76(1):60-69.e9. PubMed ID: 27663079
[TBL] [Abstract][Full Text] [Related]
3. Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial.
Gottlieb A; Sullivan J; van Doorn M; Kubanov A; You R; Parneix A; Hugot S; Milutinovic M
J Am Acad Dermatol; 2017 Jan; 76(1):70-80. PubMed ID: 27707593
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study.
Papp KA; Langley RG; Sigurgeirsson B; Abe M; Baker DR; Konno P; Haemmerle S; Thurston HJ; Papavassilis C; Richards HB
Br J Dermatol; 2013 Feb; 168(2):412-21. PubMed ID: 23106107
[TBL] [Abstract][Full Text] [Related]
5. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE).
Paul C; Lacour JP; Tedremets L; Kreutzer K; Jazayeri S; Adams S; Guindon C; You R; Papavassilis C;
J Eur Acad Dermatol Venereol; 2015 Jun; 29(6):1082-90. PubMed ID: 25243910
[TBL] [Abstract][Full Text] [Related]
6. Secukinumab in plaque psoriasis--results of two phase 3 trials.
Langley RG; Elewski BE; Lebwohl M; Reich K; Griffiths CE; Papp K; Puig L; Nakagawa H; Spelman L; Sigurgeirsson B; Rivas E; Tsai TF; Wasel N; Tyring S; Salko T; Hampele I; Notter M; Karpov A; Helou S; Papavassilis C; ;
N Engl J Med; 2014 Jul; 371(4):326-38. PubMed ID: 25007392
[TBL] [Abstract][Full Text] [Related]
7. Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: Results of the 2PRECISE study.
Mrowietz U; Bachelez H; Burden AD; Rissler M; Sieder C; Orsenigo R; Chaouche-Teyara K
J Am Acad Dermatol; 2019 May; 80(5):1344-1352. PubMed ID: 30716404
[TBL] [Abstract][Full Text] [Related]
8. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE).
Blauvelt A; Prinz JC; Gottlieb AB; Kingo K; Sofen H; Ruer-Mulard M; Singh V; Pathan R; Papavassilis C; Cooper S;
Br J Dermatol; 2015 Feb; 172(2):484-93. PubMed ID: 25132411
[TBL] [Abstract][Full Text] [Related]
9. Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study.
Ohtsuki M; Morita A; Abe M; Takahashi H; Seko N; Karpov A; Shima T; Papavassilis C; Nakagawa H;
J Dermatol; 2014 Dec; 41(12):1039-46. PubMed ID: 25354738
[TBL] [Abstract][Full Text] [Related]
10. Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3).
Reich K; Leonardi C; Lebwohl M; Kerdel F; Okubo Y; Romiti R; Goldblum O; Dennehy EB; Kerr L; Sofen H
J Dermatolog Treat; 2017 Jun; 28(4):282-287. PubMed ID: 27759463
[TBL] [Abstract][Full Text] [Related]
11. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study.
Rich P; Sigurgeirsson B; Thaci D; Ortonne JP; Paul C; Schopf RE; Morita A; Roseau K; Harfst E; Guettner A; Machacek M; Papavassilis C
Br J Dermatol; 2013 Feb; 168(2):402-11. PubMed ID: 23362969
[TBL] [Abstract][Full Text] [Related]
12. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.
Thaçi D; Blauvelt A; Reich K; Tsai TF; Vanaclocha F; Kingo K; Ziv M; Pinter A; Hugot S; You R; Milutinovic M
J Am Acad Dermatol; 2015 Sep; 73(3):400-9. PubMed ID: 26092291
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial.
Blauvelt A; Papp KA; Griffiths CE; Randazzo B; Wasfi Y; Shen YK; Li S; Kimball AB
J Am Acad Dermatol; 2017 Mar; 76(3):405-417. PubMed ID: 28057360
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
Reich K; Armstrong AW; Foley P; Song M; Wasfi Y; Randazzo B; Li S; Shen YK; Gordon KB
J Am Acad Dermatol; 2017 Mar; 76(3):418-431. PubMed ID: 28057361
[TBL] [Abstract][Full Text] [Related]
15. Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE).
Thaçi D; Humeniuk J; Frambach Y; Bissonnette R; Goodman JJ; Shevade S; Gong Y; Papavassilis C;
Br J Dermatol; 2015 Sep; 173(3):777-87. PubMed ID: 25823958
[TBL] [Abstract][Full Text] [Related]
16. Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate-to-severe plaque psoriasis: 52-week results from the CLEAR study.
Blauvelt A; Reich K; Mehlis S; Vanaclocha F; Sofen H; Abramovits W; Zhao Y; Gilloteau I; Davenport E; Williams N; Guana A; Tyring S
J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):1693-1699. PubMed ID: 28602039
[TBL] [Abstract][Full Text] [Related]
17. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
Reich K; Armstrong AW; Langley RG; Flavin S; Randazzo B; Li S; Hsu MC; Branigan P; Blauvelt A
Lancet; 2019 Sep; 394(10201):831-839. PubMed ID: 31402114
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical Trials.
Foley P; Gordon K; Griffiths CEM; Wasfi Y; Randazzo B; Song M; Li S; Shen YK; Blauvelt A
JAMA Dermatol; 2018 Jun; 154(6):676-683. PubMed ID: 29799960
[TBL] [Abstract][Full Text] [Related]
19. Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept.
Strober B; Gottlieb AB; Sherif B; Mollon P; Gilloteau I; McLeod L; Fox T; Mordin M; Gnanasakthy A; Papavassilis C; Lebwohl MG
J Am Acad Dermatol; 2017 Apr; 76(4):655-661. PubMed ID: 28087133
[TBL] [Abstract][Full Text] [Related]
20. Secukinumab Self-Administration by Prefilled Syringe Maintains Reduction of Plaque Psoriasis Severity Over 52 Weeks: Results of the FEATURE Trial.
Gottlieb AB; Blauvelt A; Prinz JC; Papanastasiou P; Pathan R; Nyirady J; Fox T; Papavassilis C
J Drugs Dermatol; 2016 Oct; 15(10):1226-1234. PubMed ID: 27741340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]